A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
|Articles|December 17, 2014
- Breast Cancer (Issue 1)
- Volume 1
- Issue 1
Obesity as a Risk Factor for Inflammatory Breast Cancer
Author(s)Beth Overmoyer, MD
Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.
Advertisement
Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, discusses obesity as a risk factor for inflammatory breast cancer.
Articles in this issue
almost 12 years ago
Breast Ultrasound Added to Mammography Increases Cancer Detectionalmost 12 years ago
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debutedalmost 12 years ago
Anti-Androgen Not for Male Cancers Alonealmost 12 years ago
Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBCalmost 12 years ago
Advances in the Treatment of HER2-Positive Breast Canceralmost 12 years ago
Immune Checkpoint Inhibition in Breast CancerAdvertisement
Related to this article
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
2
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5